A study to assess the distribution and effect of food and pH on belvarafenib in the blood of healthy adults

INTERVENTION: 1. Part 1: Cohort 1a, Sequence I: Participants will first receive a single dose of belvarafenib bis‐methanesulfonic acid salt (MSA) formulation, 400 milligrams (mg), orally, after a low‐fat meal, on Day 1, Period 1. Following an 18‐day washout period, participants will then receive a single dose of belvarafenib di‐hydrochloride salt (HCl) formulation, 400 mg, orally, after a low‐fat meal on Day 1, Period 2. 2. Part 1: Cohort 1a, Sequence II: Participants will first receive a single dose of belvarafenib HCl formulation, 400 mg, orally after a low‐fat meal on Day 1, Period 1. Following an 18‐day washout period, participants will then receive a single dose of belvarafenib MSA formulation, 400 mg, orally, after a low‐fat meal on Day 1, Period 2. 3. Part 1: Cohort 1b, Sequence I: Participants will first receive a single dose of belvarafenib MSA formulation, 50 mg, orally, after a low‐fat meal on Day 1, Period 1. Following an 18‐day washout period, participants will then receive a single dose of belvarafenib MSA formulation, 200 mg, orally, after a low‐fat meal on Day 1, Period 2. 4. Part 1: Cohort 1b, Sequence II: Participants will first receive a single dose of belvarafenib MSA formulation, 200 mg, orally, after a low‐fat meal on Day 1, Period 2. Following an 18‐day washout period, participants will then receive a single dose of belvarafenib MSA formulation, 50 mg, orally, after a low‐fat meal on Day 1, Period 2. 5. Part 2: Cohort 2a, Sequence I: Participants will first receive a single dose oral of belvarafenib MSA formulation, at dose determined in Part 1, following a high‐fat meal, on Day 1, Period 1. Following an 18‐day washout period, participants will then receive a single oral dose of be CONDITION: Healthy participants ; Not Applicable PRIMARY OUTCOME: ; 1. Cohort 1a: The geometric mean ratio (GMR) and associated 90% confidence intervals (CIs) of maximum observed plasma concentration (Cmax), concentration versus time curve from time zero extrapolated to infinity (AUC0‐8), and AUC from hour 0 to the last measurable concentration (AUC0‐t) following administration of belvarafenib HCl and belvarafenib MSA formulation after low‐fat meal; 2. Cohort 1b: Dose‐normalized Cmax, AUC0‐8, and AUC0‐t following administration of different dose levels of belvarafenib MSA formulation after low‐fat meal; 3. Cohort 2a: The GMR and associated 90% CIs of Cmax, AUC0‐8, and AUC0‐t following administration of belvarafenib MSA formulation after high‐fat meal and in the fasted state; 4. Cohort 2b: The GMR and associated 90% CIs of Cmax, AUC0‐8, and AUC0‐t following administration of belvarafenib MSA formulation alone and co‐administered with rabeprazole after low‐fat meal; ; Timeframe: PK outcomes measured using blood samples collected from Day 1 up to Day 14; INCLUSION CRITERIA: 1. Males or females of non‐childbearing potential, between 18 and 65 years of age, inclusive 2. Within body mass inde X(BMI) range 18 to 32 kilograms per square meter (kg/m^2), inclusive, at Screening 3. Females will not be pregnant or breastfeeding and must be either postmenopausal or surgically sterile. For all females, the pregnancy test result must be negative at Screening and Period 1 Check‐in (Day ‐1) 4. Negative screening test for latent Mycobacterium tuberculosis (TB) infection by QuantiFERON® TB Gold. Indeterminate results may be confirmed by repeat or by a purified protein derivative (PPD) skin test SECONDARY OUTCOME: ; 1. Cohort 1a: Time to Cma X(tmax), apparent terminal elimination rate constant (?z), terminal half‐life (t1/2), apparent systemic clearance (CL/F), and apparent volume of distribution during the terminal phase (Vz/F) following administration of belvarafenib HCl and belvarafenib MSA formulation after low‐fat meal; 2. Cohort 1b: tmax, ?z, t1/2, CL/F, and Vz/F following administration of different dose levels of belvarafenib MSA formulation after low‐fat meal; 3. Cohort 2a: tmax, ?z, t1/2, CL/F, and Vz/F following administration of belvarafenib MSA formulation after high‐fat meal and in the fasted state; 4. Cohort 2b: tmax, ?z, t1/2, CL/F, and Vz/F following administration of belvarafenib MSA formulation alone and coadministered with rabeprazole after low‐fat meal; ; Timeframe: PK outcomes measured using blood samples collected from Day 1 up to Day 14; ; 5. Incidence and severity of adverse events (AEs), incidence of abnormalities in clinical laboratory evaluations, 12‐lead ECGs, and vital signs measurements (up to approximately 84 Days);